Search results
Added:
3 years ago
Permanent pacemakers have been used to treat patients with symptomatic bradycardia for 45 years. The earliest pacemakers paced only the ventricle and were used primarily for patients with complete heart block. The need for atrial pacing became apparent as pacing for sinus node dysfunction became more common. Initially, only single-chamber pacing was possible in the atrium, and this was a good…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology, Greg Guillory
Two late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes and prior myocardial…
View more
Added:
11 months ago
ESC-HFA 23 — We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).
APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1…
View more
Added:
3 years ago
Background
Heart disease, specifically coronary artery disease (CAD), is the leading cause of death and disability among both men and women in the US. Reductions in blood supply due to narrowings of the arteries that supply the heart muscle with oxygen and nutrients (coronary arteries) result in chest pain and shortness of breath and may lead to permanent scarring of the heart muscle, as in the…
View more
Added:
3 years ago
Hypertension is a major contributor to the global disease burden and is one of the leading preventable causes of premature death worldwide.1 In the US, a disproportionate burden of hypertension and its associated complications—including coronary heart disease, heart failure, stroke, and end-stage renal disease and cardiovascular disease mortality—affect African-Americans (also referred to as US…
View more
Added:
3 years ago
Atrial fibrillation (AF) is the most commonly sustained cardiac arrhythmia observed in clinical practice with a prevalence of over 2,200,000 adults in the US.1 The prevalence of AF increases with age, from <1% among persons <60 years of age, to approximately 10% among those aged ÔëÑ80 years.2 AF is associated with an increased long-term risk of stroke, heart failure, and all-cause mortality…
View more
Added:
3 years ago
Current evidence-based therapies for ischemic heart disease include antithrombotic and antiplatelet medications that reduce the risk for ischemic outcomes such as myocardial infarction and stroke.1 Given their mechanism of action, bleeding is a risk with these agents, especially when combined with invasive procedures.2 In addition to overt bleeding, clinical trials of antithrombotic strategies…
View more
Added:
3 years ago
Permanent pacemakers have been used to treat patients with symptomatic bradycardia for 45 years. The earliest pacemakers paced only the ventricle and were used primarily for patients with complete heart block. The need for atrial pacing became apparent as pacing for sinus node dysfunction became more common. Initially, only single-chamber pacing was possible in the atrium, and this was a good…
View more
Added:
3 years ago
The use of non-vitamin K antagonist oral anticoagulants (NVKA) has revolutionized the antithrombotic treatment of patients with atrial fibrillation (AF), finally freeing them of the inconvenience and expense of international normalized ratio measurements. However, add to the equation the presence of coronary artery disease requiring percutaneous coronary intervention (PCI) with stent placement…
View more
Added:
2 years ago
In this short interview, Dr Javed Butler (University of Mississippi Medical Center, Jackson, MS, US) discusses the findings of an analysis from the EMPEROR Preserved trial. In EMPEROR-Preserved, empagliflozin treatment was associated with reduction in the risk of the primary endpoint of CV death or HF hospitalization in patients with HFpEF. In this analysis, presented at AHA 2021, the…
View more
« First